NIKI Niki BioSolutions, Inc.
Listings ·
Nasdaq's August 4, 2026 letter says the closing bid price held at $1.00 or more for ten straight business days. The 8-K gives no share price, and the company's latest annual report shows $3.5 million of cash and a material weakness in its controls.
Shareholders of both companies approved the all-stock merger on June 9, 2026. The release gives no exchange ratio, and the company's 2025 research spending was $352,879, down from $2.2 million.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $352,879 | $2.2 million |
| Net income (loss) | -$1.4 million | -$4.3 million |
| Cash from operations | -$1.8 million | -$1.2 million |
| Cash and equivalents | $3.5 million | $874,238 |
Our latest story on this, dated Jun 10, 2026: "Aptorum Group (now Niki BioSolutions) shareholders approve DiamiR merger". The story links the filing or release it is based on. Read the story.
Niki BioSolutions, Inc. trades under the ticker NIKI on NASDAQ.
Niki BioSolutions, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Niki BioSolutions, Inc. is 1734005. Its filings are on SEC EDGAR.
Our directory records Niki BioSolutions, Inc. under United States.
Our directory classifies Niki BioSolutions, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Niki BioSolutions, Inc. is US6539421023.
aibio.space lists Niki BioSolutions, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as E9.
Niki BioSolutions, Inc. reported a net loss of $1.4 million for the fiscal year ended Dec 31, 2025, and used $1.8 million of cash in operations, per its annual report to the SEC.
$352,879 in the fiscal year ended Dec 31, 2025, per its annual report.
$3.5 million in cash at Dec 31, 2025, per its 6-K.
Our latest story on Niki BioSolutions, dated Aug 7, 2026: "Aptorum Group (now Niki BioSolutions) regains Nasdaq bid price compliance". Nasdaq's August 4, 2026 letter says the closing bid price held at $1.00 or more for ten straight business days. The 8-K gives no share price, and the company's latest annual report shows $3.5 million of cash and a material weakness in its controls. Source.
From our story of Aug 7, 2026: The documents do not give a cash runway estimate or say how the company paid for its 2025 operations. Source.
Our latest listing story, dated Aug 7, 2026: "Aptorum Group (now Niki BioSolutions) regains Nasdaq bid price compliance". Nasdaq's August 4, 2026 letter says the closing bid price held at $1.00 or more for ten straight business days. The 8-K gives no share price, and the company's latest annual report shows $3.5 million of cash and a material weakness in its controls. Source.
Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,3.03,5.02,5.03,8.01,9.01). Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a merger or acquisition agreement. SEC Form 6-K. Source
Set up an at-the-market program to sell shares over time. SEC Form F-3. Source
Reported a financing. SEC Form 424B5. Source
Reported a merger or acquisition agreement. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 424B5. Source
Reported a reverse stock split. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio